Open Access

A novel melittin nano-liposome exerted excellent anti-hepatocellular carcinoma efficacy with better biological safety

Contributed equally
Journal of Hematology & Oncology201710:71

DOI: 10.1186/s13045-017-0442-y

Received: 11 February 2017

Accepted: 14 March 2017

Published: 20 March 2017

Abstract

Melittin is the main effective component of bee venom and has extensive biological functions; however, serious side effects have restricted its clinical application. Preclinical and clinical studies showed that the main adverse events were allergic reaction and pain at the administration site. To decrease the toxicity, we prepared melittin nano-liposomes by encapsulating melittin with poloxamer 188 and explored the inhibitory activities on liver cancer together with biological safety. Here, we showed that melittin nano-liposomes significantly inhibited the survival of hepatocellular carcinoma (HCC) cells in vitro and prominently suppressed the growth of subcutaneous and orthotopic HCC transplantation tumors in vivo. It was important that it induced less inflammation and allergy in mice compared with melittin. Overall, melittin nano-liposomes would have a better application in HCC therapy due to its significant anti-tumor activity and better biological safety.

Keywords

Bee venom Melittin nano-liposomes Anti-tumor activity Biological safety

Letter to the editor

Melittin is the main effective component of bee venom and has extensive biological functions in vivo, including anti-cancer property. To evaluate the anti-cancer activity of melittin on hepatocellular carcinoma (HCC), a clinical trial containing 40 HCC patients was conducted in Yancheng Second People’s Hospital (Yancheng, China). Patients with melittin treatment showed partial remission (PR) (n = 4, 10%), stable disease (SD) (n = 24, 60%), and progressive disease (PD) (n = 12, 30%), and the disease control rate (CR + PR + SD) was 70%. Toxicity was also assessable in the 40 patients. The most common adverse events were pain at the administration site and skin itch, which disappeared after melittin withdrawal (32 grade 0, 6 grade I, and 2 grade II). This results together with other preclinical studies of melittin indicated that it exerted a significant anti-HCC activity, while serious side effects have restricted the clinical application of melittin in cancer therapy [14]. To resolve these problems, melittin was modified with 2% poloxamer 188 and melittin nano-liposomes were prepared (Patent number: CN 101391098 A).

The anti-tumor activity of melittin nano-liposomes was investigated both in vitro and in vivo models (Additional file 1: Materials and methods). In the current study, we found that five hepatic carcinoma cell lines used (Bel-7402, BMMC-7721, HepG2, LM-3, and Hepa 1-6 cells) were sensitive to melittin nano-liposomes, and the IC50 value was close to melittin, ranging from 1.44 to 2.1 μM (Additional file 2: Table S1). Melittin and melittin nano-liposomes could remarkably induce cell apoptosis compared with vehicle or blank liposomes (Fig. 1a and Additional file 3: Fig. S1). Western blot analysis showed that melittin nano-liposomes (2 μM) increased the expression level of pro-apoptotic proteins, such as Bax and cleaved caspase-3, and decreased anti-apoptotic proteins, including Bcl-2 and PARP, in HepG2 cells compared with the vehicle or blank liposome group (Fig. 1b). The apoptosis process could be partly reversed by the caspase inhibitor Z-VAD-FMK (Fig. 1c). To assess the apoptosis induced by melittin nano-liposomes in vivo, a liver orthotopic xenograft tumor model of Hepa 1-6 cell was established. TUNEL assay revealed that tumor tissues of the melittin nano-liposome (2 mg/kg) group owned a larger proportion of apoptotic cells than the control or blank liposome groups, and the expression levels of apoptosis-regulated proteins in tumor tissue were also detected (Fig. 1df). Melittin nano-liposomes also showed significant inhibition of hepatocellular carcinoma growth in two nude mouse models, including the HepG2 cell subcutaneous xenograft model and LM-3-GFP cell orthotopic xenograft model (Fig. 1g and Additional file 4: Fig. S2).
Fig. 1

Melittin nano-liposomes induced apoptosis in hepatic carcinoma cells in vitro and vivo and inhibit hepatocellular carcinoma in LM-3 xenograft tumor model. a HepG2 cells were cultured with vehicle, blank liposomes (2 μM), melittin (2 μM), or melittin nano-liposomes (2 μM) for 24 h, stained with annexin V-FITC and PI, and analyzed by flow cytometry. b Western blot analysis of apoptosis-related proteins after HepG2 cells were treated with vehicle, liposomes (2 μM), melittin (2 μM), or melittin nano-liposomes (2 μM) for 24 h. c HepG2 cells were pretreated with or without the caspase inhibitor Z-VAD-FMK for 6 h and then treated with vehicle, liposomes (2 μM), melittin (2 μM), or melittin nano-liposomes (2 μM) for 24 h. Western blot analysis of Bcl-2 and procaspase-3 was carried out subsequently. d TUNEL assay for detecting apoptosis in tumor tissues of the hepatocellular carcinoma Hepa 1-6 orthotopic tumor model. e Western blot analysis of apoptosis-related proteins of Hepa 1-6 tumor tissues. f Live imaging photos and the fluorescence degree of vehicle, blank liposomes (8 mg/kg), melittin (2 mg/kg), melittin nano-liposomes (2, 4, and 8 mg/kg), and sorafenib (30 mg/kg) treated groups in the LM-3 orthotopic implanted tumor model. The data are presented as the mean ± SEM. Statistical significance was calculated using Student’s t test (*p ≤ 0.05)

To evaluate the toxicity of melittin and melittin nano-liposomes, we primarily compared the injury severity of the mouse tails in the LM-3 model where the drugs were administered. The tails of the melittin group showed severe tissue swelling and necrosis while the tails of the melittin nano-liposome group were injured less, even at a high dose of 8 mg/kg (Fig. 2a). To further compare the biological safety of melittin and melittin nano-liposomes, the drugs were intraperitoneally administered to ICR mice for 2 weeks. TUNEL assay revealed that melittin caused slight apoptosis in hepatocytes while melittin nano-liposomes showed lower toxicity to the liver tissue (Fig. 2b). Meanwhile, melittin caused a decrease of lymphocyte percentage and an increase of neutrophils in both peripheral blood and spleen, suggesting that melittin induced an inflammatory response in vivo; however, melittin nano-liposomes showed similar lymphocyte and neutrophil percentages as the control groups. Melittin induced an allergic reaction with significantly increased eosinophils and eosinophil percentage in blood, while melittin nano-liposomes effectively prevented anaphylaxis in the mice. Liposomes and melittin nano-liposomes also caused an increase of splenic B lymphocytes. (Fig. 2c and Additional file 6: Fig. S3).
Fig. 2

Melittin nano-liposomes showed reduced toxicity in vivo. a Photos of the tails of each group at the end point of treatment. These mice were from the LM-3 model. b TUNEL assay for detecting apoptosis in the liver tissue after mice (n = 10) were treated with vehicle, blank liposomes (8 mg/kg), melittin (2 mg/kg), and melittin nano-liposomes (2 mg/kg) for 2 weeks. c Peripheral blood was collected from the ICR mice and analyzed by automated hematology analyzer

In summary, our results revealed that melittin significantly delayed HCC development with certain side effects in clinic trial. Novel melittin nano-liposomes showed outstanding anti-HCC potency in vitro and in vivo with a decreased toxicity. The results potentially have clinical implications for melittin nano-liposomes as a promising new drug for HCC therapy.

Abbreviations

HCC: 

Hepatocellular carcinoma

PD: 

Progressive disease

PR: 

Partial remission

SD: 

Stable disease

Declarations

Acknowledgements

Not applicable.

Fundings

This work was supported by the National Science Foundation of China (Nos. 81673468, 91529304, 81473230, and 81403020), “Major Drug Discovery” science and technology major projects of China (No. 2011ZX09102-001-20), the 111 Project (No. 111-2-07), and Foundation of Nanjing University of Chinese Medicine (13XZR19).

Availability of data and materials

Due to our internal policy, raw data cannot be shared.

Authors’ contributions

LSJ, MJ, and AM initiated and designed the in vitro and in vivo studies. WDW and HKY performed the preclinical animal studies. LXJ performed the in vitro experiments. FJH, GXH, and YY conceived the study, participated in its design and coordination, and helped to draft the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

All animals were obtained from SLRC Laboratory Animal Co. Ltd. (Shanghai, China). Mice were bred, treated, and maintained under specific pathogen-free conditions at 24 ± 1 °C and 55 ± 5% humidity in a barrier facility with 12-h light-dark cycles. All animal experiments were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals, with the approval of center for new drug evaluation and research, China Pharmaceutical University (Nanjing, China).

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University
(2)
The Second Hospital of Nanjing
(3)
School of Pharmacy, Nanjing University of Chinese Medicine
(4)
Institute of Pharmaceutical Science, China Pharmaceutical University

References

  1. Sumikura H, Andersen OK, Drewes AM, Arendt-Nielsen L. A comparison of hyperalgesia and neurogenic inflammation induced by melittin and capsaicin in humans. Neurosci Lett. 2003;337:147–50.View ArticlePubMedGoogle Scholar
  2. Blondelle SE, Houghten RA. Hemolytic and antimicrobial activities of the twenty-four individual omission analogues of melittin. Biochemistry. 1991;30:4671–8.View ArticlePubMedGoogle Scholar
  3. Pandey BK, Ahmad A, Asthana N, Azmi S, Srivastava RM, Srivastava S, Verma R, Vishwakarma AL, Ghosh JK. Cell-selective lysis by novel analogues of melittin against human red blood cells and Escherichia coli. Biochemistry. 2010;49:7920–9.View ArticlePubMedGoogle Scholar
  4. Tosteson MT, Holmes SJ, Razin M, Tosteson DC. Melittin lysis of red cells. J Membr Biol. 1985;87:35–44.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement